Small Caps Today

Biotech

26 Articles
BioNTech’s High-Stakes Leap Into Cancer: Inside The $1.25 Billion CureVac Deal & Its Oncology Ambitions
Jun 18, 2025

BioNTech’s High-Stakes Leap Into Cancer: Inside The $1.25 Billion CureVac Deal & Its Oncology Ambitions

8' read
Bristol Myers’ $11.1 Billion Bet on BioNTech: Is Oncology The New Growth Engine?
Jun 10, 2025

Bristol Myers’ $11.1 Billion Bet on BioNTech: Is Oncology The New Growth Engine?

8' read
Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?
Jun 05, 2025

Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?

8' read
Aspire Biopharma CEO Interview: Disrupting Drug Delivery with Sublingual Tech
Mar 10, 2025

Aspire Biopharma CEO Interview: Disrupting Drug Delivery with Sublingual Tech

8' read
Is Cytokinetics The Next Big Takeover Target? Here’s What You Need to Know!
Feb 20, 2025

Is Cytokinetics The Next Big Takeover Target? Here’s What You Need to Know!

7' read
Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!
Feb 20, 2025

Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!

6' read
Legend Biotech: Why The Recent Takeover Speculation Is Worth Your Attention!
Jan 15, 2025

Legend Biotech: Why The Recent Takeover Speculation Is Worth Your Attention!

5' read
The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
Dec 04, 2024

The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics

5' read
Why Maravai LifeSciences Could Be a Perfect Acquisition Target for Repligen
s
scdadmin
·Aug 22, 2024

Why Maravai LifeSciences Could Be a Perfect Acquisition Target for Repligen

6' read
SmallCaps Daily Sits Down with Milton Werner, President and CEO of Inhibikase Therapeutics
s
scdadmin
·Feb 05, 2024

SmallCaps Daily Sits Down with Milton Werner, President and CEO of Inhibikase Therapeutics

15' read
Travere’s Recent Breakthrough Drug Sends Its Stock Soaring: What Investors Need To Know Now!
s
scdadmin
·Dec 11, 2023

Travere’s Recent Breakthrough Drug Sends Its Stock Soaring: What Investors Need To Know Now!

6' read
Pond Technologies: Value Through Vertical Integration Creates Catalysts For Investors
s
scdadmin
·Nov 11, 2021

Pond Technologies: Value Through Vertical Integration Creates Catalysts For Investors

17' read
Quipt Home Medical Corp: The Deeply Undervalued Home Medical Company Helping Create a Safer Post Pandemic World
s
scdadmin
·Aug 24, 2021

Quipt Home Medical Corp: The Deeply Undervalued Home Medical Company Helping Create a Safer Post Pandemic World

7' read
Massive Breakthrough for Young Biotech Company Longeveron, Shown in Promising Phase 2b Trial Results
s
scdadmin
·Aug 13, 2021

Massive Breakthrough for Young Biotech Company Longeveron, Shown in Promising Phase 2b Trial Results

6' read
Longeveron (LGVN): The Highest Growth Potential Company Presenting at the AAIC
s
scdadmin
·Aug 09, 2021

Longeveron (LGVN): The Highest Growth Potential Company Presenting at the AAIC

6' read
Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides’ SARS-CoV-2 Therapeutics Program
s
scdadmin
·Jul 08, 2020

Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides’ SARS-CoV-2 Therapeutics Program

9' read

Join our newsletter 🎉

Read and share new perspectives on just about any topic. Everyone’s welcome.
  • 01Create a free account.
  • 02Write your stories.
subsc